Stifel Downgrades Sarepta Therapeutic (SRPT) to Hold
Tweet
Share
E-mailGet Alerts SRPT Hot Sheet
Price: $127.39 +2.53%
Rating Summary:
30 Buy, 9 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
30 Buy, 9 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Stifel downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Buy to Hold and removed its price target (prior $46).
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $23.56 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
- Goldman Sachs Downgrades Parade Technologies Ltd. (4966:TT) to Sell
- Monster Beverage (MNST) cut to sell at Truist as its 'no longer see it as a high growth story'
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
